Clinical Trial Update: Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating DCR-PHXC-101 in normal healthy volunteers and patients with Primary Hyperoxaluria has completed, focusing on safety and pharmacology.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperoxaluria

Drugs mentioned

• DCR-PHXC-101

Snippet

Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Conditions: Primary Hyperoxaluria | Phase 1 | Status: COMPLETED